Progressive supranuclear palsy (PSP) is a rare, incurable neurodegenerative disease. It is caused by the destruction of cells in the brain due to the progressive deposition of tau protein. Currently, these tau deposits can only be detected in brain tissue after death, which is why PSP is diagnosed on the basis of clinical symptoms. Especially at the beginning of the disease, the diagnosis is fraught with uncertainty. The funded project will investigate whether tau protein can be detected by tau-PET scan using the [18F]PI-2620 tracer or in blood and cerebrospinal fluid in the early stages of the disease. This would improve the diagnostics of PSP and could be used in therapeutic trials.